Major New Drug Trial Readouts Set for the Second Half of the Year, as K-Bio Faces a Defining Moment

In the second half of this year, major biotech companies such as Kolon TissueGene and Kangstem Biotech have been releasing clinical trial results one after another. Aribio and HanAll Biopharma are also approaching data readouts, and beyond simply confirming efficacy, whether the results can lead to actual approval and commercialization is expected to become the key benchmark for judging clinical success.
According to the pharmaceutical and biotech industry on the 30th, Kangstem Biotech recently released top-line results from its Phase 2a trial of OSCA, a knee osteoarthritis treatment. In the trial of 113 patients with moderate disease, the medium- and high-dose groups showed statistically significant differences versus placebo at 24 weeks on key measures assessing pain and joint function. The MRI-based structural regeneration index, MOCART, also showed significance, confirming the possibility of structural improvement.
By contrast, Kolon TissueGene's osteoarthritis treatment TG-C failed to demonstrate statistical significance in the first of its two Phase 3 studies recently announced in the United States. Kolon TissueGene issued a formal apology to shareholders and said it would analyze the reasons for the failure. It also plans to have the ongoing second Phase 3 trial analyzed by an external statistical agency to strengthen objectivity and transparency.
An industry official explained, "In diseases such as osteoarthritis, where placebo effects can be substantial, the key criterion in clinical results has become whether the difference between the treatment group and the placebo group is statistically significant, rather than the size of the improvement alone."
In the second half of the year, clinical results from major biotech firms including Aribio and HanAll Biopharma are also expected to be released in succession.
Aribio's oral Alzheimer's disease treatment AR1001 has completed the final patient visit in a global Phase 3 trial involving 1,535 early-stage Alzheimer's patients across 13 countries. Following the top-line results, the company plans to release detailed data at the Alzheimer's Clinical Trials Conference (CTAD) in November.
The biggest point of attention is whether AR1001 achieved statistical significance versus placebo on the pre-specified primary endpoints of cognition and daily living function.
HanAll Biopharma is also awaiting results from the registration trial for its partner Immunovant's next-generation Fc receptor (FcRn) inhibitor IMVT-1402, which is under development for rheumatoid arthritis, as well as a trial for cutaneous lupus erythematosus.
The Phase 3 VELOS-4 trial of the dry eye treatment Tanfanercept is also drawing close attention. Since the earlier VELOS-3 trial failed to meet its primary endpoint, it will be important this time to secure reproducible results on the key measures.
Industry observers say the second-half trial readouts will serve as a turning point in confirming how evaluation standards are changing in Korea's biotech market. They note that, more than the mere progress of a trial, factors such as statistically significant differences versus placebo, achievement of primary endpoints, clinical meaningfulness of efficacy, consistency and reproducibility of data, and safety are becoming the key criteria for assessing corporate value.
An industry official said, "Rather than judging whether a trial has succeeded based on a few positive top-line figures, we need to look at how clearly the actual treatment effect appears across the full dataset." The official added, "The major clinical readouts in the second half of the year will be a watershed moment as Korea's biotech industry shifts from expectation-driven sentiment to validated data."
[email protected] Kang Jung-mo Reporter